Search Results - "Dybkaer, Karen"

Aspects of vincristine-induced neuropathy in hematologic malignancies: a systematic review by Madsen, Marie Lindhard, Due, Hanne, Ejskjær, Niels, Jensen, Paw, Madsen, Jakob, Dybkær, Karen

“…Purpose Vincristine is widely used as anticancer therapy for a variety of hematological malignancies. The treatment is limited by progressive…”
Get full text

DNA methylation biomarkers in peripheral blood of patients with head and neck squamous cell carcinomas. A systematic review by Danstrup, Christian Sander, Marcussen, Mette, Pedersen, Inge Søkilde, Jacobsen, Henrik, Dybkær, Karen, Gaihede, Michael

“…Head and neck squamous cell carcinomas (HNSCC) are often diagnosed in advanced stages. In search of new diagnostic tools, focus has shifted towards the…”
Get full text

Resistance to vincristine in DLBCL by disruption of p53‐induced cell cycle arrest and apoptosis mediated by KIF18B and USP28 by Rovsing, Anne Bruun, Thomsen, Emil Aagaard, Nielsen, Ian, Skov, Thomas Wisbech, Luo, Yonglun, Dybkær, Karen, Mikkelsen, Jacob Giehm

“…Summary The frontline therapy R‐CHOP for patients with diffuse large B‐cell lymphoma (DLBCL) has remained unchanged for two decades despite numerous Phase III…”
Get full text

Long Noncoding RNA Expression during Human B-Cell Development by Petri, Andreas, Dybkær, Karen, Bøgsted, Martin, Thrue, Charlotte Albæk, Hagedorn, Peter H, Schmitz, Alexander, Bødker, Julie Støve, Johnsen, Hans Erik, Kauppinen, Sakari

“…Long noncoding RNAs (lncRNAs) have emerged as important regulators of diverse cellular processes, but their roles in the developing immune system are poorly…”
Get full text

Early diagnosis of ovarian cancer based on methylation profiles in peripheral blood cell-free DNA: a systematic review by Terp, Simone Karlsson, Stoico, Malene Pontoppidan, Dybkær, Karen, Pedersen, Inge Søkilde

“…Patients diagnosed with epithelial ovarian cancer (OC) have a 5-year survival rate of 49%. For early-stage disease, the 5-year survival rate is above 90%…”
Get full text

MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index by Due, Hanne, Brøndum, Rasmus Froberg, Young, Ken H, Bøgsted, Martin, Dybkær, Karen

“…Treatment resistance is a major clinical challenge of diffuse large B-cell lymphoma (DLBCL) where approximately 40% of the patients have refractory disease or…”
Get full text

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program by Hu, Shimin, Xu-Monette, Zijun Y., Tzankov, Alexander, Green, Tina, Wu, Lin, Balasubramanyam, Aarthi, Liu, Wei-min, Visco, Carlo, Li, Yong, Miranda, Roberto N., Montes-Moreno, Santiago, Dybkaer, Karen, Chiu, April, Orazi, Attilio, Zu, Youli, Bhagat, Govind, Richards, Kristy L., Hsi, Eric D., Choi, William W.L., Zhao, Xiaoying, van Krieken, J. Han, Huang, Qin, Huh, Jooryung, Ai, Weiyun, Ponzoni, Maurilio, Ferreri, Andrés J.M., Zhou, Fan, Slack, Graham W., Gascoyne, Randy D., Tu, Meifeng, Variakojis, Daina, Chen, Weina, Go, Ronald S., Piris, Miguel A., Møller, Michael B., Medeiros, L. Jeffrey, Young, Ken H.

“…Diffuse large B-cell lymphoma (DLBCL) is stratified into prognostically favorable germinal center B-cell (GCB)–like and unfavorable activated B-cell (ABC)–like…”
Get full text

AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma by Wang, Jinfen, Xu-Monette, Zijun Y., Jabbar, Kausar J., Shen, Qi, Manyam, Ganiraju C., Tzankov, Alexandar, Visco, Carlo, Wang, Jing, Montes-Moreno, Santiago, Dybkær, Karen, Tam, Wayne, Bhagat, Govind, Hsi, Eric D., van Krieken, J. Han, Ponzoni, Maurilio, Ferreri, Andrés J.M., Wang, Shi, Møller, Michael B., Piris, Miguel A., Medeiros, L. Jeffrey, Li, Yong, Pham, Lan V., Young, Ken H.

“…AKT signaling is important for proliferation and survival of tumor cells. The clinical significance of AKT activation in diffuse large B-cell lymphoma (DLBCL)…”
Get full text

Implementing the FAIR Data Principles in precision oncology: review of supporting initiatives by Vesteghem, Charles, Brøndum, Rasmus Froberg, Sønderkær, Mads, Sommer, Mia, Schmitz, Alexander, Bødker, Julie Støve, Dybkær, Karen, El-Galaly, Tarec Christoffer, Bøgsted, Martin

“…Abstract Compelling research has recently shown that cancer is so heterogeneous that single research centres cannot produce enough data to fit prognostic and…”
Get full text

miR-155 as a Biomarker in B-Cell Malignancies by Dybkær, Karen, Roug, Anne Stidsholt, Johnsen, Hans Erik, Bøgsted, Martin, Schmitz, Alexander, Bødker, Julie Støve, Svendsen, Pernille, Due, Hanne, El-Galaly, Tarec Christoffer

“…MicroRNAs have the potential to be useful biomarkers in the development of individualized treatment since they are easy to detect, are relatively stable during…”
Get full text

The myeloma stem cell concept, revisited: from phenomenology to operational terms by Johnsen, Hans Erik, Bøgsted, Martin, Schmitz, Alexander, Bødker, Julie Støve, El-Galaly, Tarec Christoffer, Johansen, Preben, Valent, Peter, Zojer, Niklas, Van Valckenborgh, Els, Vanderkerken, Karin, van Duin, Mark, Sonneveld, Pieter, Perez-Andres, Martin, Orfao, Alberto, Dybkær, Karen

“…The concept of the myeloma stem cell may have important therapeutic implications, yet its demonstration has been hampered by a lack of consistency in terms and…”
Get full text

The mutational profile of immune surveillance genes in diagnostic and refractory/relapsed DLBCLs by Nesic, Marijana, Sønderkær, Mads, Brøndum, Rasmus Froberg, El-Galaly, Tarec Christoffer, Pedersen, Inge Søkilde, Bøgsted, Martin, Dybkær, Karen

“…Abstract Background Diffuse large B-cell lymphoma (DLBCL) is the most frequent lymphoid neoplasm among adults,and approximately 30–40% of patients will…”
Get full text

Identification of BLNK and BTK as mediators of rituximab‐induced programmed cell death by CRISPR screens in GCB‐subtype diffuse large B‐cell lymphoma by Thomsen, Emil Aagaard, Rovsing, Anne Bruun, Anderson, Mads Valdemar, Due, Hanne, Huang, Jinrong, Luo, Yonglun, Dybkær, Karen, Mikkelsen, Jacob Giehm

“…Diffuse large B‐cell lymphoma (DLBCL) is characterized by extensive genetic heterogeneity, and this results in unpredictable responses to the current…”
Get full text

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study by Xu-Monette, Zijun Y., Wu, Lin, Visco, Carlo, Tai, Yu Chuan, Tzankov, Alexander, Liu, Wei-min, Montes-Moreno, Santiago, Dybkær, Karen, Chiu, April, Orazi, Attilio, Zu, Youli, Bhagat, Govind, Richards, Kristy L., Hsi, Eric D., Zhao, X. Frank, Choi, William W.L., Zhao, Xiaoying, van Krieken, J. Han, Huang, Qin, Huh, Jooryung, Ai, Weiyun, Ponzoni, Maurilio, Ferreri, Andrés J.M., Zhou, Fan, Kahl, Brad S., Winter, Jane N., Xu, Wei, Li, Jianyong, Go, Ronald S., Li, Yong, Piris, Miguel A., Møller, Michael B., Miranda, Roberto N., Abruzzo, Lynne V., Medeiros, L. Jeffrey, Young, Ken H.

“…TP53 mutation is an independent marker of poor prognosis in patients with diffuse large B-cell lymphoma (DLBCL) treated with cyclophosphamide,…”
Get full text

CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study by Hu, Shimin, Xu-Monette, Zijun Y., Balasubramanyam, Aarthi, Manyam, Ganiraju C., Visco, Carlo, Tzankov, Alexander, Liu, Wei-min, Miranda, Roberto N., Zhang, Li, Montes-Moreno, Santiago, Dybkær, Karen, Chiu, April, Orazi, Attilio, Zu, Youli, Bhagat, Govind, Richards, Kristy L., Hsi, Eric D., Choi, William W.L., Han van Krieken, J., Huang, Qin, Huh, Jooryung, Ai, Weiyun, Ponzoni, Maurilio, Ferreri, Andrés J.M., Zhao, Xiaoying, Winter, Jane N., Zhang, Mingzhi, Li, Ling, Møller, Michael B., Piris, Miguel A., Li, Yong, Go, Ronald S., Wu, Lin, Medeiros, L. Jeffrey, Young, Ken H.

“…CD30, originally identified as a cell-surface marker of Reed-Sternberg and Hodgkin cells of classical Hodgkin lymphoma, is also expressed by several types of…”
Get full text

Human Papillomavirus Infection as a Possible Cause of Spontaneous Abortion and Spontaneous Preterm Delivery by Ambühl, Lea Maria Margareta, Baandrup, Ulrik, Dybkær, Karen, Blaakær, Jan, Uldbjerg, Niels, Sørensen, Suzette

“…Based on the current literature, we aimed to provide an overview on Human Papillomavirus prevalence in normal pregnancies and pregnancies with adverse outcome…”
Get full text

Predictive biomarkers in radioresistant rectal cancer: A systematic review by Slipsager, Anna, Henrichsen, Sofie N., Falkmer, Ursula G., Dybkær, Karen, Belting, Mattias, Poulsen, Laurids Ø.

“…The treatment of locally advanced rectal cancer often consists of neoadjuvant chemoradiotherapy followed by surgery. However, approximately 15% of patients…”
Get full text

Optimization of Preanalytical Variables for cfDNA Processing and Detection of ctDNA in Archival Plasma Samples by Nesic, Marijana, Bødker, Julie S., Terp, Simone K., Dybkær, Karen

“…DNA released from cells into the peripheral blood is known as cell-free DNA (cfDNA), representing a promising noninvasive source of biomarkers that could be…”
Get full text

Hsp90 inhibition sensitizes DLBCL cells to cisplatin by Schmidt, Linnéa, Issa, Issa Ismail, Haraldsdóttir, Hulda, Hald, Jonas Laugård, Schmitz, Alexander, Due, Hanne, Dybkær, Karen

“…Purpose Platinum-containing therapy is standard treatment for relapsed Diffuse Large B-Cell Lymphoma (DLBCL). However, the efficacy of treatment is limited by…”
Get full text

Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma by Ye, Qing, Xu-Monette, Zijun Y, Tzankov, Alexandar, Deng, Lijuan, Wang, Xiaoxiao, Manyam, Ganiraju C, Visco, Carlo, Montes-Moreno, Santiago, Zhang, Li, Dybkær, Karen, Chiu, April, Orazi, Attilio, Zu, Youli, Bhagat, Govind, Richards, Kristy L, Hsi, Eric D, Choi, William W L, van Krieken, J Han, Huh, Jooryung, Ponzoni, Maurilio, Ferreri, Andrés J M, Parsons, Ben M, Møller, Michael B, Piris, Miguel A, Winter, Jane N, Medeiros, L Jeffrey, Hu, Shimin, Young, Ken H

“…Double-hit B-cell lymphoma is a common designation for a group of tumors characterized by concurrent translocations of MYC and BCL2, BCL6, or other genes. The…”
Get full text